AC
PBYI icon

Athanor Capital’s Puma Biotechnology PBYI Stock Holding History

Athanor Capital’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-18,164
Closed -$177K – 672
2021
Q1 		$177K Buy
18,164
+4,793
+36% +$53.5K ﹤0.01% 752
2020
Q4 		$137K Hold
13,371
– – ﹤0.01% 680
2020
Q3 		$135K Sell
13,371
-10,677
-44% -$109K 0.01% 514
2020
Q2 		$251K Buy
+24,048
New +$249K 0.01% 451

Other funds holding PBYI

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Athanor Capital's PBYI Position: Q2 2021 in Review

Athanor Capital sold out of Puma Biotechnology (PBYI) in Q2 2021, closing a stake of 18,164 shares — an estimated $177K sold.

Athanor Capital first reported a position in PBYI in Q2 2020 and held it in 4 quarters. The position peaked at $251K in Q2 2020. 120 funds tracked by Wall St. Rank hold PBYI as of Q2 2021.

  • Athanor Capital reported no remaining Puma Biotechnology position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 18,164 Puma Biotechnology shares in Q2 2021, an estimated $177K.
  • Athanor Capital first reported a position in Puma Biotechnology in Q2 2020 and held it in 4 quarters.
  • Athanor Capital's Puma Biotechnology position peaked at $251K in Q2 2020.
  • 120 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.